^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)

Published date:
11/09/2020
Excerpt:
In GEP-evaluable patients receiving monotherapy (n=43), DEG analysis showed toll-like receptor (TLR) signature scores, driven by TLR8, TLR6, TIRAP, and TLR4, were positively correlated with response and survival...
DOI:
10.1136/jitc-2020-SITC2020.0079